SEC Form 4 · accession 0001209191-18-003475
Biohaven Pharmaceutical Holding Co Ltd. · BHVN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Declan Doogan
Director
Period of report
Jan 10, 2018
Accepted (ET)
Jan 12, 2018 · 7:00 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001689813
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common SharesF2 | Jan 10, 2018 | S | 23,869 | $27.13 | D | 1,276,131 | I | By The Declan Doogan 2014 Trust |
| Common SharesF3 | Jan 10, 2018 | S | 13,793 | $28.34 | D | 1,262,338 | I | By The Declan Doogan 2014 Trust |
| Common SharesF4 | Jan 10, 2018 | S | 2,600 | $29.31 | D | 1,259,738 | I | By The Declan Doogan 2014 Trust |
| Common Shares | Jan 10, 2018 | S | 100 | $29.98 | D | 1,259,638 | I | By The Declan Doogan 2014 Trust |
| Common SharesF5 | Jan 11, 2018 | S | 46,746 | $26.27 | D | 1,212,892 | I | By The Declan Doogan 2014 Trust |
| Common SharesF6 | Jan 11, 2018 | S | 1,392 | $26.77 | D | 1,211,500 | I | By The Declan Doogan 2014 Trust |
| Common SharesF7 | Jan 12, 2018 | S | 13,599 | $26.19 | D | 1,197,901 | I | By The Declan Doogan 2014 Trust |
| Common SharesF8 | Jan 12, 2018 | S | 19,843 | $26.53 | D | 1,178,058 | I | By The Declan Doogan 2014 Trust |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
- F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.81 - $27.75, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.
- F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.83 - $28.81, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4.
- F4The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.84 - $29.55, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (4) to this Form 4.
- F5The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.71 - $26.69, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (5) to this Form 4.
- F6The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.72 - $26.82, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (6) to this Form 4.
- F7The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.42 - $26.41, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (7) to this Form 4.
- F8The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.42 - $26.91, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (8) to this Form 4.